bortezomib-aft
aft pharmaceuticals ltd - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib-aft, in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib-aft, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib-aft is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
apo-bortezomib
apotex nz ltd - bortezomib 3.5mg (as mannitol boronic ester formed during finished product manufacture) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as mannitol boronic ester formed during finished product manufacture) excipient: mannitol - bortezomib in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and have progressive disease.
bortezomib - dr. reddy's
dr reddy's new zealand limited - bortezomib 3.5mg (as a mannitol boronic ester) - powder for injection - 3.5 mg - active: bortezomib 3.5mg (as a mannitol boronic ester) excipient: mannitol - bortezomib - dr. reddy's, in combination with melphalan and prednisone, is indicated for the treatment of patients with previously untreated multiple myeloma, who are not suitable for high dose chemotherapy. bortezomib - dr. reddy's as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. bortezomib - dr. reddy's is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.
bortezomib b-medical 3,5 mg inj. sol. (pwdr.) s.c./i.v. vial
b-medical b.v. - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib krka 3,5 mg inj. sol. (pwdr.) i.v./s.c. vial
krka d.d. novo mesto d.d. - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib viatris 3.5 mg inj. sol. (pwdr.) s.c./i.v. vial
viatris gx bv-srl - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib sandoz 3,5 mg inj. sol. (pwdr.) s.c./i.v. vial
sandoz sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib teva 3,5 mg inj. sol. (pwdr.) i.v./s.c. vial
teva pharma belgium sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib sandoz 2,5 mg inj. sol. (pwdr.) i.v./s.c. vial
sandoz sa-nv - bortezomib mannitol boronic ester - eq. bortezomib 2,5 mg - powder for solution for injection - 2,5 mg - bortezomib mannitol boronic ester - bortezomib
bortezomib waverley pharma europe 3,5 mg inj. sol. (pwdr.) s.c./i.v. vial
waverley pharma europe ltd. - bortezomib mannitol boronic ester - eq. bortezomib 3,5 mg - powder for solution for injection - 3,5 mg - bortezomib mannitol boronic ester - bortezomib